Dr. Logan Discusses Acalabrutinib in CLL

Video

In Partnership With:

Aaron Logan, MD, PhD, assistant professor of clinical medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses acalabrutinib (Calquence) in chronic lymphocytic leukemia.

Aaron Logan, MD, PhD, assistant professor of clinical medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses acalabrutinib (Calquence) in chronic lymphocytic leukemia (CLL).

The development of more selective agents is a general theme that has emerged in novel therapies, says Logan. In many cases, there are off-target toxicities with ibrutinib (Imbruvica), such as atrial fibrillation, and some platelet inhibition, which can lead to bleeding events.

Logan says that a more targeted Bruton's tyrosine kinase (BTK) inhibitor than ibrutinib may have some advantages. The BTK inhibitor acalabrutinib was shown to have a more favorable side effect profile, but it is not yet clear that it is superior to ibrutinib. The role of acalabrutinib has yet to be established, Logan says, but it may be beneficial for patients who cannot tolerate ibrutinib or have contraindications, such as an arrhythmia.

Related Videos
Petros Grivas, MD, PhD, professor, Clinical Research Division, Fred Hutchinson Cancer Center; professor, Division of Hematology and Oncology, University of Washington (UW) School of Medicine; clinical director, Genitourinary Cancers Program, UW Medicine
Somedeb Ball, MBBS, assistant professor, medicine, Division of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center
Phillip J. Koo, MD
Gabriella Smith, MD
Mikkael A. Sekeres, MD, MS
Francesco Di Meo, PhD
Ko Un “Clara” Park, MD
Naseema Gangat, MBBS
Erin Frances Cobain, MD
Pashtoon Murtaza Kasi, MD, MS